Dr. Orn Almarsson headshot

Dr. Örn Almarsson

Chief Technology Officer

Örn Almarsson, Ph.D., is the Technology Officer of Lyndra Therapeutics. He joined the company in 2020. Dr. Almarsson has a record of innovation and achievement in pharmaceutical R&D dating back to the mid-1990s. He has been a catalyst of design and development across drug delivery platforms as well as novel chemistry and engineering approaches to enhance and enable pharmaceutical products.

In his role as CTO, Dr. Almarsson has responsibility for early development of the Lyndra platform, including engineering, formulation, analytical R&D and process to bring products to clinical development and registration. Prior to joining Lyndra, Dr. Almarsson held roles of increasing responsibility at Moderna, Alkermes and Transform/J&J. He started his career in pharmaceutical R&D at Merck in 1995.

Dr. Almarsson is a contributor on more than 70 scientific publications, 60 patents and three book chapters. Dr. Almarsson is an avid recruiter and developer of talent in pharmaceutical science. He has contributed to team building for and development of important therapeutics and vaccines, including mRNA-lipid nanoparticle vaccine products at Moderna.

Dr. Almarsson holds a Doctorate in bioorganic chemistry from the University of California, and a Bachelor of Science in chemistry from the University of Iceland. He sits on the leadership council of the International Institute of New England, which supports immigrants coming to the area from countries like Afghanistan. A former recording artist in Iceland prior to dedicating his career to research and development in pharmaceuticals, he enjoys playing the guitar and sampling fine wines in good company.

Member Highlight